Biosimilar User Fee Negotiations Hit Snag With GPhA Gambit For Lower Fees
The Generic Pharmaceutical Association is balking at continuing to negotiate the design of a biosimilar user fee program that is independent of other user fees and has its own baseline appropriations trigger.
You may also be interested in...
Agency says pre-marketing application meetings will not be mandatory; program independence issue also appears resolved.
Senator tells FDA Commissioner Hamburg that time to market is important metric during hearing dominated by questions about medical device review.
Brand and generic drug trade associations disagree with FDA’s proposal to have biosimilar sponsors pay a product development fee before even submitting a marketing application.